Same Drug Class

Ipilimumab vs Upadacitinib

Ipilimumab vs Upadacitinib: Overview

This comparison examines the pharmacological differences between Ipilimumab and Upadacitinib.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Upadacitinib: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.

Pharmacokinetics

Half-life: Ipilimumab — 14.7 days; Upadacitinib — 9-14 hours.

Chemical Properties

Molecular Formula: Upadacitinib — C17H19F3N6O.

Molecular Weight: Upadacitinib — 380.3700 g/mol.

Type: Ipilimumab — Antibody; Upadacitinib — Small molecule.